NR1H4 and metabolic dysfunction-associated steatohepatitis: The urgent need for development of therapeutic agents for NASH has greatly increased research interest in the nuclear receptor, farnesoid X receptor (FXR, NR1H4) (Evans and Mangelsdorf, 2014).